- Dicembre 17, 2020
For media inquiries, please contact: Yin Becker, Stryker Corporation, 201-831-5000 or email@example.com This statement contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to be significantly dissomaled from forward-looking statements. All other statements, considered historical testimony, are statements that could be considered forward-looking statements, including all statements about the intent of: the current faith or expectation of the company and members of the management team and can generally be made with words such as “believe,” “wait,” “estimate,” “predict,” “potentially,” “probable,” “probably,” “run,” “could,” “could,” “plan,” “seek,” “plan,” “plan,” as well as variations and negative or negative words. Forward-looking statements include, without restriction, statements about the proposed transaction, expected performance, future plans, events, expectations, performance, objectives and opportunities, as well as the company`s business outlook; the commercial success of the company`s products, including the ability to gain broad acceptance in the company`s product market due to clinical, regulatory, reimbursement and other issues; Notifications and authorizations related to the proposed transaction The date for the completion of the proposed transaction; The possibility of closing the proposed transaction taking into account the different closing conditions; and the veracity of all the assumptions underlying one of the above hypotheses. Investors are advised that these forward-looking statements are not guarantees for future performance and involve risks and uncertainties, and are cautioned not to improperly rely on such forward-looking statements. Actual results may differ materially from expected results due to a number of risks and uncertainties. Risks and uncertainties that could cause actual results to differ from expectations reflected in forward-looking statements include: uncertainties regarding the date of the offer and other proposed transactions; Uncertainty about the number of shareholders of the company who will offer their shares in the offer or accept decisions to be taken at the extraordinary general meeting (the “CEM”); the possibility that various conditions for the completion of the proposed transaction may not be met or removed, including that a public body may prohibit, delay or deny authorization to complete the proposed transaction; The occurrence of an event, amendment or other circumstance that could lead to the termination of the sales contract; The impact of the proposed transaction (or announcement) on relationships with associated companies, customers, other counterparties or public authorities; Transaction costs the risk that the proposed transaction will divert management`s attention from the company`s day-to-day operations; Changes in the company`s operations during the period up to the close; Litigation risks and other risks and uncertainties that appear from time to time in the Company`s filings with the Securities and Exchange Commission (SEC), including updated reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as calendar 14D-9, proxy and other documents submitted by the Company.